Skip to main content

Table 1 Input data, base case

From: Health economic analysis of human papillomavirus vaccines in women of Chile: perspective of the health care payer using a Markov model

Population data  
11-years old women cohort (2012) 123,581 [18]
Screening characteristics[19]  
Regular screening coverage 57.0% [20]
Interval between regular screening 3 years [10]
Irregular screening coverage 0.0%
Population without screening 43.0% [20]
Age of initiation of screening 25 years [10]
Sensitivity to detect CIN1 58.0% [10]
Sensitivity to detect CIN2 and CIN3 61.0% [10]
Estimated positive Pap smear 1.7% [10]
Treatment performance[21]  
CIN1 detected by the screening and undergoing treatment a 40.0% [22]
Efficacy of CIN1 treatment a 100.0% [10]
CIN1 treatment effectiveness b 40.0%
CIN2 and CIN3 detected by the screening and undergoing treatment a 100.0% [10]
Efficacy of CIN 2 and 3 treatment a 90.0% [10]
CIN2 and CIN3 treatment effectiveness b 90.0%
Five-year cancer cure rate 64.0% [1]
Parameters to estimate vaccine effectiveness  
Prevalence of HPV types 16 and 18 in cervical cancer 80.0% [23]
Prevalence of other oncogenic HPV in cervical cancer 20.0% [23]
Prevalence of HPV types 16 and 18 in CIN23 46.5% [19]
Prevalence of other oncogenic HPV in CIN23 29.8% [19]
Prevalence of HPV types 16 and 18 in CIN1 36.5% [19]
Prevalence of other oncogenic HPV in CIN1 42.9% [19]
Prevalence of HPV types 6 and 11 in CIN1 15.8% [19]
Prevalence of HPV types 6 and 11 in GW 76.2% [24]
Vaccine efficacy to HPV types16 and 18 CC (HPV-16/18 & HPV-6/11/16/18 vaccines) 98.0%/98.0% [2527]
Vaccine efficacy to HPV types16 and 18 CIN23 (HPV-16/18 & HPV-6/11/16/18 vaccines) 98.0%/98.0% [2527]
Vaccine efficacy to HPV types16 and 18 CIN1 (HPV-16/18 & HPV-6/11/16/18 vaccines) 98.0%/98.0% [2527]
Vaccine efficacy to other oncogenic HPV CC (HPV-16/18 & HPV-6/11/16/18 vaccines) 68.4%/32.5% [2831]
Vaccine efficacy to other oncogenic HPV CIN23 (HPV-16/18 & HPV-6/11/16/18 vaccines) 68.4%/32.5% [2831]
Vaccine efficacy to other oncogenic HPV CIN1 (HPV-16/18 & HPV-6/11/16/18 vaccines) 47.7%/23.4% [28, 29, 32]
Vaccine efficacy to HPV types 6 and 11 for HPV-6/11/16/18 vaccine 98.0% [33, 34]
Costs[35] US dollars
Pap smear cost (including false positive tests) 26.19
GW treatment 62.00
CIN1 treatment & follow-up cost 1,636.00
CIN2 and CIN3 treatment & follow-up cost 1,636.00
Cervical cancer treatment 13,218.00
Cost per vaccinated woman (price parity between vaccines) c 60.00
  1. aExpert opinion; ES; bCalculated; cPrice parity at 20 US dollars per dose were used.
  2. Note: CIN: cervical intraepithelial neoplasia; HPV: human papillomavirus; US: United States.
\